T-E Meds Inc., established in 2022, is the second subsidiary of T-E Pharma Holding. We utilize our Multi-Arm Linker technology platform to develop diverse Drug Bundles, which are site-specifically conjugated to antibodies. Through a streamlined and efficient manufacturing process, we produce high-purity, high Drug-to-Antibody Ratio (DAR) antibody-drug conjugates (ADCs) and antibody-radionuclide conjugates (ARCs) with excellent stability, solubility, and homogeneity.

Based on this design, we have developed multiple ADC and ARC drug candidates for the treatment of hard-to-treat cancers, including multiple myeloma, pancreatic cancer, and HER2-related malignancies. These candidates are currently in preclinical development.

Another affiliated company, the sister company of T-E Meds – Immunwork, Inc., was established in 2014. The innovative fatty acid bundle platform has been applied to develop the ultra-long-acting drug candidates for the treatment of critical endocrine diseases, such as diabetes, obesity, acromegaly and neuroendocrine tumors. Two promising candidates are in Phase I clinical trial now.  

Immunwork website: https://www.immunwork.com/